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~zrzlt~z~ut~ ~ ~ hyp~retemla  (hFH) Is assocq- 
ated wire an ~ risk of ~ .  The aim of mm sludy was Io 
datem'dne me evofulmn el daseendl~g thorac¢ aomz alhemmatous dmease 
(TAA) by ~ erhoca~gfa l~ (lqEE) m hFl-I patients after 
Io~-tem~ ~ mera~t ~ d~ and stam~r,. Sixteen patrols (7 
maim and 9 ~male~ mean age 47 ~ 12 yrs) wilh f~y  diagnoe, d hFH 
o:~mpased the study populatk0~t. An p~beofs unOefwerff a baseline TEE ex- 
aalatat~ ~r  wl~dl ~ ¢'t~[31 (:rz~1 alibi p r ' ~  (L~[)-40 n~ o.d) were 
initiated. ~ t  TEE was ped~m~ed after 2 y,zs of therapy. TAA was graded 
as follows: grede 0: no,real i r~a;  g~de |: inoreased intimal ecbede~s~ 
lh~ck~H~l o r lunlen t~j.d~t~; ~cld~. It: ~ illt~mal 
s~ w~h sm~ ~dl-defmed ameromatous i~que proWudmg .:3 mm intothe 
lun, m~ grade IlL ~ allleremas I~01n~ng <3 ram; grade IV: atheremas 
protmdm0 >3 n~ glade V: protmdm9 mollie of pedunculated ptaquas. 
~ :  As a result o~ treofment, LDL decreasea frem 294 _+ 56 n~O/dl to 
193 ~ 56 n~'dl (p < 0.025). Accoofin9 te beselme TEE, I pt was grada 0, 4 
pts were grade I, 6 pts were grade II, 3 pts were grade III and 2 were grade 
IV. Two years lat~ 7 pts did not change c~tegory, 3 pts showed prograsS~on 
of TAA (1 pt flora, gr-~de II to grade Ill and 2 pts from grade III to grade IV), 
v~le 6 pts showed re~-esston ot TAA (3 pts from made t to grade. 0 I~  
tram ~ It to grade o. 1 pt from It to ! and 1 pt from IV to III). Paben~ 
who improved We~B younger (39 ± 14 vs 52 ± 6 yrs, p < 0.025) rind less 
severe pretreatment TAA and had a greater LDL decrease (138 ± 56 vs 72.5 
54.5 mg,k;g, p < 0.025), compared with patients who remained stable or 
deteriorated. 
In ~on.  ior~ten'~ hypot@Ktemic d~et and treatment v~th pravestatm 
is ettectwe in produ~m~j TAA regressmn in young hFH pts with moderate 
atheromatesis. TEE is a v'alual~e method for the evaluation of these changes. 
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Despite benefits of cholesterol owering treatment seen in eadier tnats, treat- 
ment effect on mortality in patients ,~th relat~ety hernial cholesterol levels 
has remained uncertain. The LIPID trial assessed long term effects of pravas- 
latin versus p~acebo ~n 9,104 patients with baseline total choleste rot of 4.0.-7.0 
mmol/L (155-271 m~cli) and a history of acute myocardial infarction (5,754; 
64%) or hospitalisation for unstable angina (3,260; 361). Major treatment 
outcomes included coronary mortality, total mortality, myocardial infarction, 
and stroke. The study was also designed to assess treatment effects by 
baseline lipids and changes in lipids on subsequent outcomes. The study 
included large numbers with relatively tow initia| cholesterol evels: 3,793 
(42%) with total cholasterol <5.5 mmoPL (213 mg]dl) and 2,678 (,30°/,4 v~th 
LDL cholesterol <3.5 mmol,l_ (136 mg/dl). 
Interim analysis has shown clear evidence of a reduction in total mortality 
with pravastatin (p < 0.003) and so the LIPID trial is clesing early with final 
analysis to be undertaken after patient visits are completed by September 30, 
1997. The relationship between baseline lipid levels and relative reductions 
in coronary events will be examined as well as the effect of lipid changes on 
subsequent coronary risk. Th=s large scale trial should enable the relationship 
of treatment effects with pravastatin and lipids to be estimated much more 
reliably. 
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C~f~v~n (CER) m a~ novel HMG.COA n~:luc~ mt~ltef I~  reduel~ 
chek~-leml level= ~t ~r~tow 00~es. Pmv~ ~tu~e~ up Io 0.¢ ~} pmdu¢~ 
a Io9 I~r  ¢lo~mspomm cu~ wflh LOL-¢bOk~t~ol (LDL.C) ~ of 
36%. 
~ -  To c~m,m~_ em ~ e~l ufmy at rERm 0,O m0~y 
~ -  In th~ 2B day mndomt~t~ doub~-bl~, pla¢~o (PLA),o~.. 
troUe¢l ~ II If~, 41 pltl~l~ ~ ~ ~ , , a  m 
t~ll~lL,~ on an AHA Ste~ I diet foe 4 'MN~J l~f  t~ ~ tO CER 
0.8 mO (n = 281 or PL~ (n = 13), ¢l~ly tn Ihe evef~l, LOL¢, t0tal rhOle~4m:d 
(1oral.C), HOL.C, ~ (TRIG) lind Lp(a) wefli~  m ~-...~,~ 
i ~ ,  All adv~me veofs were ~ .  
F~U/IS.' Chan~ =n I~  par~ (% from harm at each post,treat. 
ment vmtl) were as ~low~: 
Day a Day 1,5 Day 22 Day 29 
Parameter PLA CER PLA CER PLA CER Pl~ CER 
LDL-C F.0 -325 41 -37,?. 31 -434 1 2 -440 
To~aI.C 1 7 239 2.4 ~2e3 3.7 -301 ~ -30e 
HOL-C 20 20 - t2 1.0 31 2e -12 32 
TRIG -43 -14.5 t02 -18.9 96 -B7 159 -112 
CER s~gmficamty reduced tetal-C, LDL-C and l~ty~ftde ~ compare0 
m PLA Reduction~ m IoW-C and LDL-C were appmem after a days, and 
mammal by Day 22. All !paints completed the 2&-day treatment course. 
Ot~e patient, m the Iou~t~ week of treatme~ wilh CER, day.aped peh~c 
i n ~  disease. No patient e~l~ited ALT or AST elevatJ~ greater 
man2 ,, ULN. One patent, t~ l~ l  w~h CER a~e¢ l  an a~,pton-.a~ 
inc~rease in CK (8 ~ ULN) oft gle last day of Irealm~t. This value relumed 
to near nownel mx days la~. 
~ :  CER 0.8 mg produced an LDL-C raduction of 441 eon=s~mt 
with a continued tog linear dose ~ of 6% adl~nal LDL-C reduction 
for every CtDu~ng el dose. This rs~tt.¢tton m¢ompara~a with the t~he~ 
doses of the most effective stat~rts cu~ marketed 
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Ba~grounu. A simvastatm-treated subgroup, not reduong recurrence oi ma. 
lor coronary e~s ,  was ,~Bparaled horn 45 by high ba~d seru~ cholestanol 
and plant sterol and low precursor sterol ratios suggesting that they had 
hfgh absotpl~m and low synff~emis of cholesterol. We assumed tt~t the 
non-respon~rs might be more ~ to ~ostand est~ mmgmme 
(SEM)-induced c~asterel ma~L-~on.  
Method: From a coronary group treated over a year with stmvastatm, 
higllest (H;n = 15) and lowest (L'n = 15) absorbers were s~Heofed by glair 
basal chofestano~cholesterel ratio and treated for 3 monff~ with SEM. 
Resu/ts.- Basal total and LDL choleslerel values and 1heir simvaMalkl-ln- 
duced redudions were similar in H and L while the re~:,~h/e cholestrnol 
and plant sterol ratios were 1.6-1,9 times higher in H than L Addition of SEM 
further decreased total (-7.6 ± 2~/=) and LDL (-11.7 + 3.51) cholesterol 
in H (P < 0.01). while in L the reductions were nonsignificant. Reductions 
of cholestanol and plant sterol ratios and the increases of precursor sterol 
ratios were similar in the two groups. 
Conclusion: Coronary patients on simvastattn with high baseline rhotas- 
tarot absorption are benefitled tram sttostanol-induced cholesterol malab- 
sorption as compared to those w~th.low absorption and high synthesis. Non- 
responsiveness to stalin may contribute to lacking recurrence of coronary 
events. 
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Decrease of Recurrent Coronary Events 
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Ba,.,~ground: InScandinavian Sir'm, astatin Survival Study (4S) stmvestatin-in- 
duced ,eduction of coronary events (CE) was not predicted by baseline Iipids. 
The increasing quartiles at the t~as~l cholesterol (C) precursor steml (IS)/C 
